Research
Hormonal
GLP-1 receptor agonists (semaglutide 2.4 mg, tirzepatide) produce significantly greater weight loss than older pharmacotherapies (liraglutide, orlistat, phentermine/topiramate) and provide cardiovascular benefits.
If lifestyle changes alone are insufficient, newer GLP-1 medications like semaglutide (2.4 mg weekly) offer significantly higher weight loss (approx. 15%) compared to older drugs. Discuss these options with your doctor, keeping in mind that cost and insurance coverage may be barriers.
StrongSupportsVERY_HIGH confidence
Semaglutide is a major breakthrough in the treatment of obesity as the degree of weight loss achieved is nearly twice that seen with other approved anti-obesity treatments. Tirzepatide was associated with 15% weight reduction with 5 mg weekly doses, 19.5% with 10 mg doses and 20.9% with 15 mg doses... Semaglutide 2.4 mg was evaluated in the STEP trials... showed a weight loss of 14.8%... compared with 2.4% in the placebo group.
Why this rating
Supported by large RCTs (STEP, SURMOUNT) with clear, significant effect sizes.
Source
Obesity in the Asia-Pacific Region: Current Perspectives
David Tak Wai Lui et al. · Journal of Asian Pacific Society of Cardiology · 2024
DOI 10.15420/japsc.2023.68
narrative_reviewCited 30×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Asian populations develop obesity-related cardiometabolic morbidities at lower BMI thresholds than white populations, necessitating lower diagnostic cutoffs (BMI ≥25 or 27.5 kg/m²) for accurate risk identification.Good
- Lifestyle interventions (caloric restriction, physical activity, behavioral changes) are critical components for obesity management, with a target of 5-10% weight loss over 6 months being an appropriate initial goal.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →